CAMBRIDGE, Mass.--(BUSINESS WIRE)--ARIAD Pharmaceuticals, Inc. (Nasdaq: ARIA) announced the completion of its previously announced underwritten offering of 3,112,945 shares of its common stock. The shares were sold to Credit Suisse Securities (USA) LLC, the sole underwriter, at a price of $4.65 per share, providing proceeds to the Company of $14.5 million, or $14.3 million after deducting expenses of the offering. Credit Suisse Securities (USA) LLC has an option to purchase up to an additional 466,942 shares of ARIAD’s common stock which expires on November 18, 2006. Following this offering, the Company has used all of the shares available for issuance under its effective shelf registration statements.
